

Table of Contents

Guest Editor for this issue:

Kristin Highland, MD, MSCR

Assistant Professor
Division of Pulmonary and Critical
Care Medicine
Director, Pulmonary Hypertension Clinic
Medical University of South Carolina
Charleston, South Carolina

- 264 Profiles in Pulmonary Hypertension:
Virginia D. Steen, MD
- 277 International Corner:
Combination Therapy in PAH
- 278 CME Section
- 280 Pulmonary Hypertension
in Systemic Lupus
Erythematosus
- 286 Pulmonary Hypertension and
the Antiphospholipid
Syndrome
- 292 Scleroderma Associated
Pulmonary Hypertension
- 299 CME Self-Assessment
Examination
- 301 Pulmonary Hypertension
Roundtable: PAH and
Scleroderma

Publisher

Pulmonary Hypertension Association
Michael D. McGoon, MD, *Chair of the Board*
Rino Aldrighetti, *President*
Donica Merhazion, *Associate Director of Medical Services*

PHA Office

Pulmonary Hypertension Association
801 Roeder Rd. Suite 400
Silver Spring, MD 20910-4496
301-565-3004, 301-565-3994 (fax)
www.phassociation.org

© 2008 by Pulmonary Hypertension Association. All rights reserved. None of the contents may be reproduced in any form whatsoever without the written permission of PHA.

ISSN: 1933-088X (print); 1933-0898 (online)

Editorial Offices

Advances in Pulmonary Hypertension, DataMedica,
P.O. Box 1688, Westhampton Beach, NY 11978
Tel (631) 288-7733 Fax (631) 288-7744
E-mail: sbelsenchapman@aol.com

Publishing Staff

Stu Chapman, *Executive Editor*
Susan Chapman, *Managing Editor*
Heidi Green, *Associate Editor*
Gloria Catalano, *Production Director*
Michael McClain, *Design Director*

Advances in Pulmonary Hypertension is circulated to cardiologists, pulmonologists, rheumatologists, and other selected physicians by the Pulmonary Hypertension Association. The contents are independently determined by the Editor and the Editorial Advisory Board. All past issues of the journal are available at: www.PHAssociation.org/Medical/Advances_in_PH/

Cover Image

This illustration symbolizes the malar ("butterfly") rash that is characteristic of patients with systemic lupus erythematosus. The artwork was provided by Martin J. Somskey.

Guest Editor's Memo

Targeting the Connection Between PAH and Connective Tissue Disease



Pulmonary hypertension (PH) is associated with all of the connective tissue diseases (CTDs), but it is most commonly seen in systemic sclerosis (scleroderma), followed by systemic lupus erythematosus, and the antiphospholipid antibody syndrome. Although the prognosis for CTD-associated PH has improved with the availability of numerous pulmonary arterial hypertension therapies, it still carries a substantially poorer prognosis than idiopathic pulmonary arterial hypertension, and necessitates additional research into its treatment and prevention.

Further complicating treatment, CTD-associated PH is often multifactorial and can be caused by any of the World Health Organization categories of PH. In this issue of *Advances in Pulmonary Hypertension*, the contributors review what is known regarding the epidemiology, pathobiology, and treatment of PH, with a focus on pulmonary arterial hypertension in systemic sclerosis, systemic lupus erythematosus, and antiphospholipid syndrome.—**Kristin B. Highland, MD, MSCR**

Editor's Memo

Highlighting Current and Future Perspectives in the Journal



The recent increase in awareness and recognition of pulmonary hypertension is in part related to the efforts of Rheumatologists who are now screening many of their patients for this deadly disease. This issue, guest edited by Dr Kristin Highland, focuses on the spectrum of connective tissue diseases and their relation to pulmonary hypertension. While there is still much to learn about how and why patients with connective tissue diseases develop pulmonary hypertension, the benefits of treatment for many of these patients are apparent. This issue also spotlights rheumatologist,

Dr Virginia Steen, whose efforts in the world of pulmonary hypertension, particularly on screening and early diagnosis, are close to my heart. For our new International Corner, Dr Nick Morrell provides commentary on combination therapy issues covered in the previous issue of *Advances*, with an international perspective.

I am pleased to preview important content to be published in *Advances in Pulmonary Hypertension* in the next 2 issues. The journal will be focusing on 2 meetings held earlier this year that provided relevant and timely updates on pulmonary hypertension. First, physicians who were unable to attend the World Health Organization 4th World Symposium on Pulmonary Hypertension will be pleased to see the next issue and its comprehensive discussion of key findings from this meeting. Among the topics to be covered are: current perspectives on pathophysiology, diagnosis and assessment of pulmonary arterial hypertension (PAH), interventional and surgical modalities, endpoints and clinical trial design in PAH, as well as inflammation, growth factors, and pulmonary vascular remodeling.

In the following issue, the journal will feature content from another important meeting, this year's 8th International Conference and Scientific Sessions of the Pulmonary Hypertension Association. The information from this meeting will be gleaned from physicians who led the sessions and who are among the leading investigators in the field. We look forward to providing articles on these important issues and welcome your feedback. Please send your comments and suggestions to our executive editor at Stulink@aol.com.

Ronald J. Oudiz, MD
Editor-in-Chief

Editorial Advisory Board

Editor-in-Chief

Ronald J. Oudiz, MD
Associate Professor of Medicine
UCLA School of Medicine
Director, Liu Center for Pulmonary
Hypertension
Division of Cardiology
Los Angeles Biomedical Research
Institute at Harbor-UCLA
Medical Center
Torrance, California

Immediate Past Editor

Vallerie V. McLaughlin, MD
Associate Professor of Medicine
Director, Pulmonary Hypertension
Program
University of Michigan Health System
Ann Arbor, Michigan

Editor-in-Chief Elect

Richard Channick, MD
Professor of Clinical Medicine
Pulmonary and Critical Care Division
University of California, San Diego
Medical Center
San Diego, California

Associate Editors

Erika Berman Rosenzweig, MD
Assistant Professor of Pediatrics
Department of Pediatrics
Columbia College of Physicians
and Surgeons
New York, New York

Todd Bull, MD
Associate Professor of Medicine
Medical Director, ICU Anshutz
Inpatient Pavilion
Division of Pulmonary Sciences and
Critical Care Medicine
University of Colorado Health Sciences
Center
Denver, Colorado

Robert Schilz, DO, PhD
Medical Director of Lung Transplantation
and Pulmonary Vascular Disease
University Hospital of Cleveland
Case Western Reserve University
Cleveland, Ohio

Editorial Board

Teresa De Marco, MD
Director, Heart Failure and
Pulmonary Hypertension Program
University of California, San Francisco
San Francisco, California

Eli Gabbay, MD
Associate Professor
University of Western Australia
School of Medicine and Pharmacology
Medical Director, Advanced Lung Disease
and Pulmonary Vascular Unit
Royal Perth Hospital
Perth, Australia

Kristin Highland, MD
Assistant Professor
Division of Pulmonary and Critical
Care Medicine
Director, Pulmonary Hypertension Clinic
Medical University of South Carolina
Charleston, South Carolina

Omar Minai, MD

Staff Physician
Cleveland Clinic
Cleveland, Ohio

Myung H. Park, MD

Director, Pulmonary Vascular
Diseases Program
University of Maryland School of
Medicine
Baltimore, Maryland

Ioana Preston, MD

Assistant Professor of Medicine
Tufts-New England Medical Center
Boston, Massachusetts

Zeenat Safdar, MD

Assistant Professor of Medicine
Department of Medicine,
Pulmonary & Critical Care Section
Pulmonary Hypertension Center
Baylor College of Medicine
Houston, Texas

Rajan Saggat, MD

Assistant Professor of Medicine
Division of Pulmonary and Critical Care
Medicine and Hospitalists
David Geffen School of
Medicine at UCLA
Los Angeles, California

Francisco Soto, MD

Assistant Professor
Director, Pulmonary Hypertension
Program
Medical College of Wisconsin
Milwaukee, Wisconsin

Fernando Torres, MD

Director, Pulmonary Hypertension
Program
UT Southwestern Medical Center
Dallas, Texas

Program Description

The mission of *Advances in Pulmonary Hypertension* is to serve as the premiere forum for state of the art information regarding diagnosis, pathophysiology, and treatment of pulmonary hypertension. The 2003 Venice revision of the World Health Organization Classification serves as a guide to categories of pulmonary hypertension addressed by the Journal. While focusing on WHO Group I PAH, the other categories (Group II, Left heart disease; Group III, Associated with lung disease and/or hypoxemia; Group IV, Thrombotic and/or Embolic Disease; Group V, Miscellaneous) are also addressed. This mission is achieved by a combination of invited review articles, Roundtable discussions with panels consisting of international experts in PH, and original contributions. In addition, a special section entitled "Profiles in Pulmonary Hypertension" recognizes major contributors to the field and serves as an inspiring reminder of the rich and collegial history of dedication to advancing the field.

Objectives

- Provide up-to-date information regarding diagnosis, pathophysiology, and treatment of pulmonary hypertension.
- Serve as a forum for presentation and discussion of important issues in the field, including new paradigms of disease understanding and investigational trial design.
- Recognize and preserve the rich history of individuals who have made major contributions to the field via dedication to patient care, innovative research, and furthering the mission of the PH community to cure pulmonary hypertension.

The Scientific Leadership Council of the Pulmonary Hypertension Association

The scientific program of the Pulmonary Hypertension Association is guided by the association's Scientific Leadership Council. The Council includes the following health care professionals:

Vallerie V. McLaughlin, MD
SLC Chair
University of Michigan Health System
Ann Arbor, Michigan

David B. Badesch, MD
SLC Immediate Past Chair
University of Colorado Health
Sciences Center
Denver, Colorado

John H. Newman, MD
SLC Chair Elect
Vanderbilt Medical School
Nashville, Tennessee

Robyn J. Barst, MD
New York, New York

Raymond L. Benza, MD
University of Alabama Health System
Birmingham, Alabama

Todd Bull, MD
University of Colorado Health
Sciences Center
Denver, Colorado

Richard N. Channick, MD
UCSD Medical Center
San Diego, California

C. Gregory Elliott, MD
LDS Hospital
University of Utah School of Medicine
Salt Lake City, Utah

Karen A. Fagan, MD
University of South Alabama
College of Medicine
Mobile, Alabama

Adaani Frost, MD
Baylor College of Medicine
Houston, Texas

John Granton, MD
Toronto General Hospital
Toronto, Canada

Nazzareno Galìè, MD
Institute of Cardiology
University of Bologna
Bologna, Italy

Nicholas S. Hill, MD
Division of Pulmonary, Critical Care
and Sleep Medicine
Tufts-New England Medical Center
Boston, Massachusetts

Marius Hoeper, MD
Hannover Medical school
Hannover, Germany

Dunbar Ivy, MD
University of Colorado Health
Sciences Center
Denver, Colorado

Zhi-Cheng Jing, MD
Fu wai Heart Hospital
Beijing, China

Anne M. Keogh, MD
St. Vincent's Public Hospital
Sydney, Australia

Michael J. Krowka, MD
Mayo Clinic
Rochester, Minnesota

James E. Loyd, MD
Vanderbilt University Medical Center
Nashville, Tennessee

Michael D. McGoon, MD
Chair, PHA Board of Trustees
Pulmonary Hypertension Clinic
Mayo Clinic
Rochester, Minnesota

Srinivas Murali, MD
Allegheny General Hospital
Pittsburgh, Pennsylvania

Ronald J. Oudiz, MD
Liu Center for Pulmonary Hypertension
Los Angeles Biomedical Research
Institute
Harbor-UCLA Medical Center
Torrance, California

Marlene Rabinovitch, MD
Stanford University School of Medicine
Stanford, California

Erica Berman-Rosenzweig, MD
Columbia-Presbyterian Medical Center
New York, New York

Ivan M. Robbins, MD
SLC Scientific Sessions Committee
Vanderbilt University
Nashville, Tennessee

Julio Sandoval, MD
Cardiopulmonary Department
National Institute of Cardiology
of Mexico
Tlalpan, Mexico

Richard Silver, MD
Medical University of South Carolina
Charleston, South Carolina

Victor F. Tapson, MD
Division of Pulmonary and Critical
Care Medicine
Duke University Medical Center
Durham, North Carolina

Liaisons

Arlene Schiro, RN, MA, ACNP-BC
Chair, PH Resource Network
Massachusetts General Hospital
Boston, Massachusetts

Joanne Sperando Schmidt
Patient Liaison

Emeritus Members

Bruce H. Brundage, MD
St. Charles Medical Center-Bend
Bend, Oregon

Alfred P. Fishman, MD
University of Pennsylvania Health
System
Philadelphia, Pennsylvania

The Mission of the Scientific Leadership Council is to provide medical and scientific guidance and support to the PHA by:

- Developing and disseminating knowledge for diagnosing and treating pulmonary hypertension
- Advocating for patients with pulmonary hypertension
- Increasing involvement of basic and clinical researchers and practitioners

More information on PHA's Scientific Leadership Council and associated committees can be found at:
www.PHAAssociation.org/SLC/